Document is current
Any future updates will be listed below
-
Authors
Song, Zehan
Park, Sang Hee
Mu, Wei-Chieh http://orcid.org/0000-0003-2669-7312
Feng, Yufan
Wang, Chih-Ling
Wang, Yifei
Barthez, Marine
Maruichi, Ayane
Guo, Jiayue
Yang, Fanghan
Lin, Anita Wong
Heydari, Kartoosh
Chini, Claudia C. S.
Chini, Eduardo N. http://orcid.org/0000-0003-1555-4834
Jang, Cholsoon
Chen, Danica http://orcid.org/0000-0001-9169-4973
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01AG082105, R01DK117481, R01AG063404, R01AG063389, R01 AG26094, R01 AG58812, R01 CA233790, R01 AA029124)
United States Department of Agriculture | National Institute of Food and Agriculture
Dr. and Mrs. James C.Y. Soong Fellowship, Taiwan Government for Study Abroad Scholarship, QB3 Frontiers in Medical Research Fellowship
the ITO Scholarship, JASSO Graduate Scholarship for Degree Seeking Students
- License Information
-
More Information
Article History
Received: 1 November 2023
Accepted: 18 June 2024
First Online: 23 July 2024
Competing interests
: E.N.C. holds a patent on the use of CD38 inhibitors for metabolic diseases that is licensed by Elysium Health. E.N.C. is a consultant for TeneoBio, Calico, Mitobridge and Cytokinetics. E.N.C. is on the advisory board of Eolo Pharma. E.N.C. owns stocks in TeneoBio. Research in the Chini laboratory has been conducted in compliance with the Mayo Clinic conflict of interest policies. The other authors declare no competing interests.
